Top News

Mymetics’ promising HIV vaccine candidate obtains funding to begin study at Texas Biomedical Research Institute

SBA Member News, 30.09.2014

Mymetics Corporation (OTCQB: MYMX), a pioneer in
the research and development of virosome-based vaccines to prevent transmission of human
infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine
candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial.


Next Event


Community Login

Bachem Holding AG

 Wissenschaft im Gespraech | Den Naturwissenschaften fehlt der Nachwuchs | Schweizer Radio DRS

The potential in the land

LRC TriCEPS™ technology

BBC - End of Drug Discovery